Jaguar Health, Inc. current report, 21 February 2020

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on February 27, 2020, covering events occurring on February 21, 2020. The company is an emerging growth company incorporated in Delaware and trades on the NASDAQ Capital Market.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

On February 21, 2020, two directors resigned from the Board of Directors:

  • Jeffery Johnson: Resigned as a director and member of the Compensation and Nominating Committees.
  • Murray David MacNaughtan: Resigned as a director.

Both directors were originally designated by Sagard Capital Partners, L.P. pursuant to rights associated with the Company's Series A Convertible Participating Preferred Stock. The resignations occurred because Sagard's aggregate voting power fell below the 5% threshold required to maintain director designation rights. The company stated there was no disagreement with management or the Board regarding these departures.

Updated Board Committee Composition

Following the resignations, the Board committees are now composed as follows:

  • Audit Committee: Messrs. Micek, Bochnowski, and Siegel.
  • Compensation Committee: Messrs. Bochnowski and Siegel.
  • Nominating Committee: Messrs. Bochnowski and Micek.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, outlook, management commentary on operations, or specific risk factors beyond the governance change described.

Key Facts for Investor Verification

  • Verify the current ownership percentage of Sagard Capital Partners, L.P. to confirm the loss of director designation rights.
  • Confirm the qualifications and independence of the remaining board members (Micek, Bochnowski, Siegel) following the reduction in board size.
  • Review the resignation letters (Exhibits 99.1 and 99.2) for any additional context not summarized in the main text.
  • Check subsequent filings for the appointment of new directors to replace the resigned members, if applicable.